# Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

> **NCT02255097** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 172 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT02255097
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-24
- **Primary completion:** 2016-04-22
- **Final completion:** 2021-06-18
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02255097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02255097, "Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02255097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*